Table 2.
Patient characteristics after propensity score matching.
| Non-secondary cancer (n=322) | Secondary cancer (n=322) | P | |
|---|---|---|---|
| Age (year) | 0.672 | ||
| median | 59 | 58 | |
| IQR | 51-67 | 52-65 | |
| Race | 0.751 | ||
| asian | 116 (36.0%) | 106 (32.9%) | |
| black | 30 (9.3%) | 37 (11.5%) | |
| white | 10 (3.1%) | 10 (3.1%) | |
| other | 166 (51.6%) | 169 (52.5%) | |
| Sex | 0.860 | ||
| female | 90 (28.0%) | 87 (27.0%) | |
| male | 232 (72.0%) | 235 (73.0%) | |
| Grade | 0.741 | ||
| I | 7 (2.2%) | 8 (2.4%) | |
| II | 32 (10.0%) | 34 (10.6%) | |
| III | 96 (29.8%) | 100 (31.1%) | |
| IV | 108 (33.5%) | 92 (28.6%) | |
| unknown | 79 (24.5%) | 88 (27.3%) | |
| Pathology | 0.345 | ||
| WHO I | 65 (20.2%) | 74 (23.0%) | |
| WHO II | 108 (33.5%) | 119 (37.0%) | |
| WHO III | 73 (22.7%) | 70 (21.7%) | |
| other | 76 (23.6%) | 59 (18.3%) | |
| T stage | 0.991 | ||
| 1 | 114 (35.4%) | 114 (35.4%) | |
| 2 | 89 (27.6%) | 91 (28.3%) | |
| 3 | 59 (18.4%) | 60 (18.6%) | |
| 4 | 60 (18.6%) | 57 (17.7%) | |
| N stage | 0.489 | ||
| 0 | 85 (26.4%) | 94 (29.2%) | |
| 1 | 128 (39.8%) | 109 (33.9%) | |
| 2 | 79 (24.5%) | 87 (27.0%) | |
| 3 | 30 (9.3%) | 32 (9.9%) | |
| AJCC | 0.326 | ||
| I | 23 (7.1%) | 35 (10.9%) | |
| II | 109 (33.9%) | 95 (29.5%) | |
| III | 102 (31.7%) | 104 (32.3%) | |
| IV | 88 (27.3%) | 88 (27.3%) | |
| Chemotherapy | 0.091 | ||
| no | 26 (8.1%) | 40 (12.4%) | |
| yes | 296 (91.9%) | 282 (87.6%) |
IQR: interquartile range. WHO: World Health Organization. AJCC: American Joint Committee on Cancer.